Peroral endoscopic myotomy in patients with idiopathic achalasia
1. In this multicenter randomized trial, peroral endoscopic myotomy (POEM) generated clinical success in controlling symptoms of achalasia similar to the current gold standard...
Ultra-processed foods linked to increased risk of type 2 diabetes
1. In this prospective cohort study from France, consumption of ultra-processed foods (UPF) was linked to an increased risk of type 2 diabetes (T2D).2....
Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled...
1. Certain dietary supplements, including vitamin B12, iron and omega-3 fatty acids, may negatively impact disease-free survival and overall survival in breast cancer patients...
Obeticholic acid for the treatment of non-alcoholic steatohepatitis
1. Obeticholic acid, a farnesoid X receptor agonist, prompts fibrosis improvement in patients with non-alcoholic steatohepatitis (NASH)Evidence Rating Level: 1 (Excellent)Non-alcoholic steatohepatitis (NASH) is an...
Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi...
1. Enterotoxigenic Escherichia coli vaccination may provide significant immunogenic benefits in young children and infants in low- and middle-income countries with minimal associated toxicity.Evidence...
Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk...
1. Dose escalation of rectal indomethacin does not provide any benefit in preventing pancreatitis in high-risk patients post-endoscopic retrograde cholangiopancreatography.Evidence Rating Level: 1 (Excellent)Pancreatitis...
Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for...
1. Laparoscopic-assisted distal gastrectomy is non-inferior to open distal gastrectomy for clinical stage IA and IB gastric cancer in terms of relapse-free survival at...
Risk of major adverse cardiovascular events varies with dynamic metabolic syndrome status
1. In this retrospective study involving South Koreans with no history of major adverse cardiovascular events (MACE), persons who developed metabolic syndrome (MetS) within...
Combined Encorafenib-Binimetinib-Cetuximab therapy associated with longer overall survival in patients with BRAF V600E-mutated coloreactal...
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) and a MEK inhibitor...
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings...
1. After adjustment for established cardiovascular risk factors, the diagnosis of non-alcoholic fatty liver disease (NAFLD) does not appear to be associated with risk...
